TD Cowen analyst Tyler Van Buren reiterated a Buy rating and $15.00 price target on Travere Therapeutics (NASDAQ: TVTX).

The analyst commented, "The voluntary pause pushes back enrollment completion for the peg HARMONY trial to 2026, which will also delay the topline 2026 readout. However, the company remains highly optimistic regarding the potential of pegtibatinase and expects strong patient interest when enrollment resumes. This was of minor focus for investors, and we don't expect the stock to be down much. Our PT is under review."

For an analyst ratings summary and ratings history on Travere Therapeutics click here. For more ratings news on Travere Therapeutics click here.

Shares of Travere Therapeutics closed at $15.04 yesterday.